tradingkey.logo

Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R)

ReutersJun 25, 2025 12:24 PM

- Amneal Pharmaceuticals Inc AMRX.O:

  • AMNEAL HIGHLIGHTS POSITIVE TOPLINE RESULTS FROM CONFIRMATORY CLINICAL STUDY OF BIOSIMILAR CANDIDATE TO XOLAIR(R) (OMALIZUMAB), DEVELOPED BY KASHIV BIOSCIENCES

  • AMNEAL PHARMACEUTICALS INC - ADL-018 CLINICAL STUDY ACHIEVES PRIMARY AND SECONDARY ENDPOINTS

  • AMNEAL PHARMACEUTICALS INC - BLA FOR ADL-018 EXPECTED TO BE SUBMITTED TO FDA IN Q4 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI